Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05749029
Other study ID # Hetashi Bawa MRP 2021
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 1, 2023
Est. completion date December 12, 2023

Study information

Verified date March 2024
Source Canterbury Christ Church University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this research study is to evaluate a programme that is based on Compassionate Mind Training (CMT) over four-weeks. The programme intends to share information and strategies to reduce diabetes distress, self-criticism, and shame, and improve physical health in people who have Type 1 and Type 2 Diabetes Mellitus.


Description:

This Randomised Controlled Trial (RCT) will compare a CMT intervention for people with Type 1 and Type 2 Diabetes Mellitus with a waitlist control group who will be given access after the study. The outcome measures will be completed at baseline (week 0), post-intervention (week 4), and at follow-up (week 8).


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date December 12, 2023
Est. primary completion date October 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Resident in the United Kingdom; - Clinician diagnosed Type 1 Diabetes Mellitus or Type 2 Diabetes Mellitus; - Self-managing condition; - Diabetes diagnosed over a year ago. Exclusion Criteria: - Diagnosis of Gestational Diabetes or Pre-Diabetes. - Current severe mental health condition; - Currently self-harming or suicidal; - Currently engaging in psychological therapy.

Study Design


Intervention

Behavioral:
Four Week Self-Compassion Course
This is a four-week self-compassion course supplied by Balanced Minds. The owner of Balanced Minds is a Consultant to this study, who will be providing access to participants. The self-help, self-compassion course is based on Compassionate Mind Training. This provides participants with opportunities to develop skills and attributes of compassion through a weekly 30-minute video on a specified topic, a 10-minute compassionate exercise that participants are encouraged to engage in daily for the week and a brief summary of the compassionate topic. The topics of the course are: The Foundations of Self-Compassion Developing your Compassionate Self Deepening the Compassionate Relationship with Yourself Self-compassion in Everyday Life.

Locations

Country Name City State
United Kingdom Salomons Institute for Applied Psychology, Canterbury Christ Church University, 1 Meadow Road Tunbridge Wells

Sponsors (1)

Lead Sponsor Collaborator
Canterbury Christ Church University

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Diabetes Distress Scale (DDS) scores from baseline (week 0) to post-intervention (week 4). The DDS is a 17-item measure of problems and hassles related to diabetes.
The DDS establishes a total mean score and a mean score for its four sub-scales. Scores will range from 1 to 6. Mean scores of 3 or above is considered distress worthy of clinical attention.
Post-intervention (week 4)
Secondary Change in the total score on the External and Internal Shame Scale (EISS) from baseline (week 0) to post-intervention (week 4). The EISS is an eight-item scale measuring external and internal dimensions of shame.
Higher scores indicate higher levels of shame and a total score varies between 8 and 40.
Post-intervention (week 4)
Secondary Change in Forms of Self-Criticising/Attacking and Self-Reassuring Scale (FSCRS) scores from baseline (week 0) to post-intervention (week 4). The FSCRS is a 22-item scale with statements measuring inadequate self, hated self and reassured self.
Scores will range from 0 to 88.
Post-intervention (week 4)
Secondary Change in Fears of Compassion Scale (FCS) scores from baseline (week 0) to post-intervention (week 4). The FCS is a 15-item measure of fear of compassion towards self.
Scores will range from 0 to 60. Higher scores indicate greater fear of compassion.
Post-intervention (week 4)
Secondary Change in Warwick-Edinburgh Mental Wellbeing Scales (WEMWBS) scores at baseline (week 0) and post-intervention (week 4). 14-item measure assessing mental wellbeing in the non-clinical sample. Scores on the WEMWBS will range from 14 to 70. Higher scores indicate greater positive mental wellbeing. Post-intervention (week 4)
Secondary Change in Compassionate Engagement and Action Scale (CEAS) scores at baseline (week 0) and post-intervention (week 4). The CEAS is a 13-item measure of compassionate engagement and action.
The engagement sub-scale will establish a score between 6 and 60.
The action sub-scale will establish a score between 4 and 40.
Post-intervention (week 4)
Secondary Change in HbA1c from baseline (week 0) to follow-up (week 8). Participants will be asked to self-report a blood glucose (HbA1c) level taken by a healthcare provider in the past three to six months at baseline and at one-month post-intervention.
Higher HbA1c levels indicate poorer diabetes control.
Follow-up (week 8)
Secondary Change in Warwick-Edinburgh Mental Wellbeing Scales (WEMWBS) scores at baseline (week 0) and follow-up (week 8). Please see description above. Follow-up (week 8)
Secondary Change in the total score on the External and Internal Shame Scale (EISS) from baseline (week 0) to follow-up (week 8). Please see description above. Follow-up (week 8)
Secondary Change in Forms of Self-Criticising/Attacking and Self-Reassuring Scale (FSCRS) scores from baseline (week 0) to follow-up (week 8). Please see description above. Follow-up (week 8)
Secondary Change in Diabetes Distress Scale (DDS) scores from baseline (week 0) to follow-up (week 8). Please see description above. Follow-up (week 8)
Secondary Change in Fears of Compassion Scale (FCS) scores from baseline (week 0) to follow-up (week 8) Please see description above. Follow-up (week 8)
Secondary Change in Compassionate Engagement and Action Scale (CEAS) scores at baseline (week 0) to follow-up (week 8). Please see description above. Follow-up (week 8)
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A